Insomnia and Sleep Disturbances in Chronic Pain Patients - Relation to Physical Activity Level and Opioid Use
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Martin Olsson, MD
- Phone Number: +46-31-3435816
- Email: martin.olsson@gu.se
Study Locations
-
-
-
Gothenburg, Sweden
- Recruiting
- Pain Centre, Department of Anaesthesiology and Intensive Care Medicine Östra, Sahlgrenska University Hospital, Region Västra Götaland
-
Contact:
- Martin Olsson, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Chronic pain (i.e. pain > 3 months)
- Planned follow up at the Pain Centre
- Age ≥18 years
- Consents to participation in the study
Exclusion Criteria:
- Inadequate knowledge of the Swedish language
- Alcohol or substance abuse
- Severe untreated psychiatric disorders including psychiatric disease and/or psychological conditions which are the primary determinant to the patient's pain condition
- Malignant disease with short expected survival
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Accelerometry
Recording of sleep and physical activity by accelerometry during one week.
|
Recording of sleep and physical activity by accelerometry during one week.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sleep
Time Frame: Daily assessment during one week
|
Sleep duration in minutes assessed by accelerometry
|
Daily assessment during one week
|
|
Sleep
Time Frame: Daily assessment during one week
|
Sleep timing, i.e. sleep onset and wake time assessed by accelerometry
|
Daily assessment during one week
|
|
Physical activity
Time Frame: Daily assessment during one week
|
Minutes of physical activity per week at moderate and vigorous intensity physical activity (MVPA), minutes of sedentary behaviour (SED) assessed by accelerometry
|
Daily assessment during one week
|
|
Opioid consumption
Time Frame: Opioid consumption at study enrollment
|
Opioid consumption in morphine equivalent doses
|
Opioid consumption at study enrollment
|
|
Pain intensity
Time Frame: Daily assessment during one week
|
Pain intensity according to Numeric Rating Scale (NRS), score from 0 to 10, where 0 is described as "no pain" and 10 as "worst pain imaginable"
|
Daily assessment during one week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Insomnia Severity
Time Frame: Insomnia severity at enrollment
|
Total Score from the 7-item Insomnia Severity Index where total score ranges from 0-28 and higher scores indicate greater severity of insomnia.
|
Insomnia severity at enrollment
|
|
Sleep quality
Time Frame: Sleep quality at study enrollment
|
Assessed with the Pittsburgh Sleep Quality Index (PSQI).
The PSQI consists of 19 self-rated questions which assess a wide variety of factors relating to sleep quality, including estimates of sleep duration and latency and of the frequency and severity of specific sleep related problems.
The 19 items are grouped into seven component scores, each weighted equally on a 0-3 scale.
The seven component score are then summed to yield a global PSQI score which has a range of 0-21; higher scores indicate worse sleep quality.
|
Sleep quality at study enrollment
|
|
Daytime sleepiness
Time Frame: Daytime sleepiness at study enrollment
|
Epworth Sleepiness Scale (ESS), which quantifies daytime sleepiness.
The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24.
The higher the ESS score, the higher daytime sleepiness.
|
Daytime sleepiness at study enrollment
|
|
Self-assessed physical activity
Time Frame: Self-assessed physical activity at study enrollment
|
Minutes of physical activity per week (physical exercise and daily exercise) and minutes of sedentary behaviour per week.
|
Self-assessed physical activity at study enrollment
|
|
Self-efficacy for exercise scale
Time Frame: Self-efficacy for exercise at study enrollment
|
The Self-efficacy for exercise scale measures a patient's self-efficacy when it comes to physical exercise.
The questionnaire consists of 9 questions that can be answered on a 1-10 scale.
A total score between 9 and 90 is calculated, were a higher number represent a better outcome.
|
Self-efficacy for exercise at study enrollment
|
|
Mental fatigue scale
Time Frame: Mental fatigue at study enrollment
|
The mental fatigue scale (MFS) is a multidimensional questionnaire containing 15 questions.
A total score between 0-42 is calculated.
A score >10 indicates a problem with mental fatigue.
|
Mental fatigue at study enrollment
|
|
Sleep dairy
Time Frame: Daily assessment during one week
|
Self-assessed sleep latency, total sleep time, wake time after sleep onset and sleep quality.
|
Daily assessment during one week
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neurofilament light
Time Frame: Neurofilament light at study enrollment
|
Neurofilament light in blood sample
|
Neurofilament light at study enrollment
|
|
25-hydroxyvitamin D
Time Frame: 25-hydroxyvitamin D at study enrollment
|
Levels of Serum 25-hydroxyvitamin D (25[OH]D)
|
25-hydroxyvitamin D at study enrollment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Paulin Andréll, MD, PhD, Sahlgrenska University Hospital, Region Västra Götaland; Göteborg University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 272924
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.